Novel Mechanisms of Progesterone Antagonists and Progesterone Receptor
@article{Edwards2000NovelMO, title={Novel Mechanisms of Progesterone Antagonists and Progesterone Receptor}, author={Dean P. Edwards and Susan A. Leonhardt and Elizabeth K. Gass-Handel}, journal={Journal of the Society for Gynecologic Investigation}, year={2000}, volume={7}, pages={S22 - S24} }
The progesterone receptor (PR), as a member of the nuclear receptor superfamily of ligand-dependent transcription factors, activates gene transcription through binding to specific palindromic progesterone response elements (PRE) in the promoter region of progestin-responsive genes. The progesterone antagonists ZK98299 (Onapristone) and RU 486 (Mifepristone) inhibit the transcriptional activity of PR by complex mechanisms at concentrations much lower than the progestins. Altered conformation is…
Figures from this paper
19 Citations
Mechanism of Action of Progesterone Antagonists
- BiologyExperimental biology and medicine
- 2002
The first clinically used progesterone antagonist RU486 and closely related compounds are discussed and cellular factors that may influence the activity of these compounds, such as the availability of coactivators and corepressors and the context of specific target promoters in any given cell type are discussed.
Determination of conformational changes in the progesterone receptor using ELISA-like assays
- Biology, ChemistrySteroids
- 2006
Signal Transducer and Activator of Transcription 3 Is Expressed in the Decidualized Mesometrium of Pregnancy and Associates with the Progesterone Receptor Through Protein-Protein Interactions1
- BiologyBiology of reproduction
- 2002
Observations suggest thatSTAT3 expression is a prevalent feature of progesterone action, and that STAT3 and PR interactions represent a convergence of diverse signal transduction pathways in the decidualized mesometrium during pregnancy.
Dominant Role of Nuclear Progesterone Receptor in the Control of Rat Periovulatory Granulosa Cell Apoptosis1
- BiologyBiology of reproduction
- 2009
It is shown that P4 regulates apoptosis in periovulatory granulosa cells by acting via the classic nuclear receptor.
Inhibition of prostaglandin F2α synthesis and oxytocin receptor by progesterone antagonists in bovine endometrial cells in vitro
- Biology, MedicineSteroids
- 2006
Differential expression of uterine calcium transporter 1 and plasma membrane Ca2+ ATPase 1b during rat estrous cycle.
- BiologyAmerican journal of physiology. Endocrinology and metabolism
- 2006
Results suggest that CaT1 is regulated by P4 at diestrus via a PR-dependent pathway, andCaT1 mRNA was expressed in uterine endometrium and glandularEndometrium atdiestrus in P4-treated rats.
Steroid Hormone Modulation of Prostaglandin Secretion in the Ruminant Endometrium During the Estrous Cycle1
- BiologyBiology of reproduction
- 2004
The purpose of this article is to review the recent data related to how progesterone and estradiol could regulate (initiate and then turn off) the uterine pulsatile secretion of PGF2α observed at luteolysis.
Comparative transcriptome profiling and characterization of gene expression for ovarian differentiation under RU486 treatment.
- BiologyGeneral and comparative endocrinology
- 2018
Progestins and antiprogestins affect gene expression in early development in zebrafish (Danio rerio) at environmental concentrations.
- BiologyEnvironmental science & technology
- 2012
Effects on the hormone system are elucidated by quantitative determination of transcriptional changes of target genes induced by 2, 20, and 200 ng/L P4, RU486, norethindrone (NET), and levonorgestrel (LNG).
References
SHOWING 1-10 OF 11 REFERENCES
The Nuclear Corepressors NCoR and SMRT Are Key Regulators of Both Ligand- and 8-Bromo-Cyclic AMP-Dependent Transcriptional Activity of the Human Progesterone Receptor
- BiologyMolecular and Cellular Biology
- 1998
It is proposed that 8-bromo-cAMP-mediated potentiation of PR transcriptional activity is due, at least in part, to a disruption of the interaction between PR and the corepressors NCoR and SMRT.
The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT.
- BiologyMolecular endocrinology
- 1997
The data suggest that the direction of transcription by antagonist-occupied steroid receptors can be controlled by the ratio of coactivators to corepressors recruited to the transcription complex by promoter-bound receptors.
Agonist and antagonists induce homodimerization and mixed ligand heterodimerization of human progesterone receptors in vivo by a mammalian two-hybrid assay.
- BiologyMolecular endocrinology
- 1998
It is proposed that antiprogestin inactivation of PR in trans by heterodimerization contributes to the biological potency of these compounds.
Two Types of Anti-progestins Have Distinct Effects on Site-specific Phosphorylation of Human Progesterone Receptor (*)
- Biology, ChemistryThe Journal of Biological Chemistry
- 1996
The results indicate that the biological effects of RU486 are not mediated by an alteration in the phosphorylated state of PR, whereas failure to promote phosphorylation of certain sites may contribute to the antagonist action of ZK98299, and support the concept of two mechanistic classes of anti-progestins that affect PR differently in vivo.
Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation.
- Biology, ChemistryThe Journal of biological chemistry
- 1992
Progesterone inhibition of occupancy by PR in response to progestins or antagomnsts SUp P - casein expression involves PR and Stat 5 interactions
- 1998
Progesteronc inhibition of j3-casein expression involves PR and Stat 5 interactions
- Endocrine Society, Abstract
- 1998
Coregulatory proteins in nuclear hormone receptor a PRE half - site in the proximal f - casein promoter located adja - action
- Vitamins and Hormones
- 1999
Ligands induce confonnational changes in the carboxyl-tern linus of progesterone receptors which are detected by a site-directed monoclonal antibody
- Mol Endocrinol
- 1992